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Abstract
Background: In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy
(CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of the metabolic syndrome (MS)
and its components, and to determine whether patients with or without CL had a different prevalence of MA.
Methods: We evaluated 345 HIV-infected patients on cART using two different MS definitions (NCEP-ATPIII-2005
and IDF-2005) and the Framingham risk score.
Results: CL was present in 58.7% of the patients. The prevalence of the MS was 52.2% (ATPIII) and 43.2% (IDF), and
it was not significantly different between patients with (W) or without (WT) CL, regardless of the definition used
(ATPIII WCL 52.9% vs WT CL 51.1%; p = 0.738; IDF WCL 41.3% vs WTCL 46.0%; p = 0.379). Moderate concordance
was observed between the 2 definitions (kappa = 0.484; p < 0.001) and after gender stratification there was good
concordance in women (kappa = 0.759; p < 0.001). Patients with CL had lower waist circumference and HDL-C and
higher triglycerides levels. In women, CL was significantly associated with MS, hypertriglyceridemia and low HDL
cholesterol independently of age, cART and BMI. Patients with CL had a significantly higher risk of coronary heart
disease at 10 years, measured by the Framingham risk score, than patients without CL. Those with CL and with MS
had higher frequencies of moderate and high risk categories than those without MS.
Conclusions: The prevalence of the MS was high in these HIV-infected patients with an age average of 40 years
and this finding could explain why HIV patients have an increased risk for cardiovascular disease (CVD).
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Background
Combination antiretroviral therapy (cART) has changed
the course of HIV infection, leading to a significant
reduction in AIDS related morbidity and mortality [1].
However, cART is known to be associated with changes
in fat distribution (lipodystrophy) and metabolic abnorm-
alities, including insulin resistance, dyslipidemia, and
increased blood pressure (BP) [2,3].
The Metabolic syndrome (MS), a common condition in
the general population, refers to a constellation of
cardiovascular disease (CVD) risk factors, including
increased waist circumference (WC), glucose and lipid
metabolism disorders, and hypertension [4,5]. Each of
these risk factors individually increases cardiovascular
risk, but the MS itself has shown to be a powerful inde-
pendent risk factor for cardiovascular morbi-mortality
and diabetes [6]. It is still controversial if the MS
improves the identification of high risk individuals [7-9].
HIV-infected lipodystrophic patients share several com-
ponents of the MS. The prevalence of the MS in HIV-
infected patients has been reported to range from 4.4 to
45.4% [9-23].
HIV-lipodystrophy is considered to be an adverse
effect of cART, not limited to a specific drug or class of
drugs [24]. It seems to affects up to half or even more
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HIV-infected patients receiving cART [25]. However,
few studies address the prevalence of the MS in patients
with lipodystrophy [12,14,17].
The aim of this study was to evaluate the prevalence
of the MS and of its five individual components in HIV-
infected patients on cART and to determine whether
patients with or without CL had a different prevalence
of MA.
Methods
Subjects
As part of a cross-sectional study, 345 non-institutiona-
lized, HIV-infected Caucasian adults (239 males), on
cART referred from the Infectious Diseases to the Endo-
crinology Out-patient Clinic of Hospital São João due to
lipodystrophy or any metabolic disorders were included.
Only patients on cART were included, since lipodystrophy
is mainly related to ART drugs. The study protocol was
approved by the Hospital’s Ethical Committee and all
patients provided informed consent.
Clinical assessment
For each patient the following information was collected,
using a standardized protocol: demographic data (age,
gender), duration of HIV infection, history of diabetes,
hypertension, use of antidiabetic, antihypertensive or lipid-
lowering drugs and duration of cART. Weight, height,
WC and resting BP were measured as previously described
[26]. Body weight was measured using TANITA (Tanita®,
model TBF 300) scale and height was measured to the
nearest centimetre in the standing position using a wall
stadiometer (Holtain Limited Crymych, Dyfed®).
Clinical lipodystrophy (CL) and central fat accumulation
or abdominal prominence, were defined as previously
described [27]. All clinical assessments were performed by
the same practitioner (PF). Patients were classified in 4 dif-
ferent groups according to the presence or absence of
either lipoatrophy or abdominal prominence: group 1- No
lipodystrophy (patients without clinical lipoatrophy and
without abdominal prominence); group 2- Isolated cen-
tral fat accumulation (patients without clinical lipoatro-
phy and with abdominal prominence); group 3- Isolated
lipoatrophy (patients with clinical lipoatrophy and with-
out abdominal prominence); group 4- Mixed forms of
lipodystrophy (patients with clinical lipoatrophy and with
abdominal prominence).
A venous blood sample was drawn after a 12-hour over-
night fast. All the samples were analyzed at the central
laboratory of our hospital. Plasma glucose, total choles-
terol, HDL cholesterol (HDL-C) and triglycerides were
determined using automatic standard routine enzymatic
methods. Hepatitis C was diagnosed by HCV-Ab serosta-
tus. The CD4+ cell count was determined by flow
cytometry and plasma RNA-VIH was measured by a
quantitative reverse transcriptase polymerase chain reac-
tion, which had a lower limit of detection of 50 copies/mL.
Metabolic Syndrome definitions
Two different MS definitions were used: the Third Report
of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (ATPIII) modified by
American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement (AHA/NHLBI) in
2005 [28] and the International Diabetes Federation (IDF)
definition [29].
The Framingham cardiovascular risk score was calcu-
lated for all patients using the Framingham methodology
as reported by Wilson. It incorporates age, gender, systolic
blood pressure, lipids, glucose, and smoking status into a
model that predicts the probability of coronary heart dis-
ease risk at 10 years [30].
Statistical analysis
Data were presented as mean and standard deviation (SD)
for quantitative variables when normally distributed.
When the variable distribution was different than the nor-
mal, it was expressed as median and respective 25th and
75th percentiles. For comparison between quantitative
variables Student-t test and the Mann-Whitney test were
used when appropriate. Categorical variables were
described as counts and proportions, and compared using
the chi-square or Fisher’s exact test. Kappa coefficients
were estimated to analyze the statistical agreement
between ATP III as modified by the AHA/NHLBI and IDF
definitions of MS.
Odds ratios and their respective 95% confidence inter-
vals (CI) were computed using unconditional logistical
regression models. The association between lipodystrophy
and the presence of MS and its individual components
was estimated after adjustment for sex, age, cART dura-
tion and BMI, whenever appropriate.
Statistical analysis was performed using the SPSS version
17.0 software (SPSS Inc., Chicago, Illinois, USA). All prob-
abilities were two tailed and p values < 0.05 were regarded
as significant.
Results
Of the 345 HIV-1 infected patients on cART included in
this study, 58.7% presented CL. Table 1 shows the charac-
teristics of the study sample according to the presence of
CL. Patients with CL were more frequently male, older,
had longer duration of infection, longer duration of cART
and lower weight, BMI and WC. Also, this group of
patients had significantly higher CD4+ cell counts and a
significantly higher prevalence of virological suppression.
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Table 1 Sample characteristic according to the presence of clinical lipodystrophy
Without CL With CL P
n (%) 139 (39.6) 206 (58.7)
Sex [n(%)]
Male 85 (61.2) 154 (74.8) 0.007
Female 54 (38.8) 52 (25.2)
Age [years, median (25th and 75th percentiles)] 42.0 (34.0-51.0) 45.0 (39.0-54.0) 0.006
Duration of HIV infection [years, median (25th and 75th percentiles)] 6.0 (4.0-9.0) 9.0 (6.0-11.0) < 0.001
cART [years, median (25th and 75th percentiles)] 4.0 (2.0-7.0) 8.0 (5.0-10.0) < 0.001
Weight [Kg, mean (sd)] 73.6 (14.1) 66.2 (12.4) < 0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.430
BMI [(kg/m2), mean (sd)] 27.0 (5.0) 24.0 (3.9) < 0.001
Waist circumference [cm, mean (sd)] 95.4 (13.0) 89.5 (10.5) < 0.001
Systolic BP [mmHg, median (25th and 75th percentiles)] 120.0 (110.0-135.0) 120.0 (110.0-135.0) 0.871
Diastolic BP [mmHg, median (25th and 75th percentiles)] 80.0 (70.0-80.0) 80.0 (70.0-80.0) 0.765
CD4 cell count [cells/mm3, median (25th and 75th percentiles)] 446.5 (291.5-633.8) 544.0 (362.0-749.0) 0.008
HIV RNA (< 50) [n (%)] 94 (82.5) 163 (91.1) 0.029
Hepatitis C co-infection [n (%)] 31 (25) 58 (31.4) 0.227
HIV risk factor [n (%)]
Intravenous drug user 28 (24.6) 52 (30.6)
Homosexual contact 10 (8.8) 19 (11.2)
Heterosexual contact 75 (65.8) 90 (52.9)
Others 1 (0.9) 9 (5.3) 0.073
CDC [n (%)]
A 62 (54.9) 94 (53.4)
B 4 (3.5) 0 (0.0)
C 47 (41.6) 82 (46.6) 0.037
ART [n (%)]
IP 67 (61.5) 98 (55.4) 0.310
NNRTI 47 (43.1) 83 (46.9) 0.534
NRTI 104 (95.4) 175 (98.9) 0.066
Smoking history [n (%)]
Never 60 (43.5) 70 (34.8)
Current 56 (40.6) 93 (46.3)
Former 22 (15.9) 38 (18.9) 0.272
Glucose [mg/dL, median (25th and 75th percentiles)] 91.0 (84.0-108.0) 94.5 (863.0-117.0) 0.074
Total cholesterol [mg/dL, mean (sd)] 229.5 (59.8) 220.7 (59.5) 0.182
HDL- cholesterol [mg/dL, median (25th and 75th percentiles)] 48.0 (37.0-55.0) 43.0 (35.0-53.0) 0.047
Triglycerides [mg/dL, median (25th and 75th percentiles)] 192.0 (126.0-323.0) 231.0 (149.8-365.8) 0.016
Metabolic syndrome ATP III [n (%)] 71 (51.1) 109 (52.9) 0.738
Metabolic syndrome IDF [n (%)] 64 (46.0) 85 (41.3) 0.379
Metabolic syndrome features - ATP III
High blood pressure 61 (43.9) 87 (42.4) 0.790
Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
High waist circumference 58 (41.7) 46 (22.3) < 0.001
High fasting glucose 51 (36.7) 84 (40.8) 0.446
Number of metabolic syndrome features ATP III
0 6 (4.3) 9 (4.4) 0.242
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No significant differences in HIV risk factors or in cART
regimen composition were found between patients with or
without CL. The prevalence of hepatitis C co-infection
was 28.8%, without significant differences between patients
with or without CL. No significant differences were found
in smoking history (never, current or former) between
patients with or without CL, however, patients who were
current smokers had the highest frequency of low and
normal weight and those who never smoked had the high-
est frequency of overweight and obesity (data not shown).
No significant difference was found in fasting glucose
according to smoking history (data not shown). According
to the presence of CL, no differences were found in systo-
lic and diastolic BP, glucose and total cholesterol levels.
However, patients with CL had lower HDL-C and higher
triglycerides plasma levels (Table 1).
Regarding BMI distribution, men and women with CL,
were more frequently classified as normal when com-
pared to those without CL. Those without CL were
more frequentely classified as overweight (Table 2).
Metabolic syndrome
In our sample, the prevalence of MS was 52.2% and
43.2%, according to ATPIII and IDF criteria, respectively.
No significant differences in the prevalence of the MS
were observed in patients with or without CL, regardless
of the definition used (table 3). Moderate concordance
was observed between the 2 definitions (kappa = 0.484;
p < 0.001). After gender stratification, moderate agree-
ment was observed in men (kappa = 0.374; p < 0.001),
and good agreement in women (kappa = 0.759; p <
0.001). Using both MS criteria, no significant differences
in the prevalence of CL were found between patients
with and without MS [[with MS 60.6% (109 patients) vs
without MS 58.8% (97 patients); p = 0.822 for ATPIII]
and [with MS 57.0% (85 patients) vs without MS 61.7%
Table 1 Sample characteristic according to the presence of clinical lipodystrophy (Continued)
1 25 (18.0) 19 (9.3)
2 37 (26.6) 69 (33.7)
3 31 (22.3) 52 (25.4)
4 31 (22.3) 42 (20.5)
5 9 (6.5) 14 (6.8)
Metabolic syndrome features - IDF
High blood pressure 61 (43.9) 87 (42.4) 0.790
Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
High waist circumference 87 (62.6) 94 (45.6) 0.002
High fasting glucose 51 (36.7) 80 (38.8) 0.687
Number of metabolic syndrome features IDF
0 5 (3.6) 9 (4.4) 0.263
1 19 (13.7) 17 (8.3)
2 35 (25.2) 51 (24.9)
3 32 (23.0) 63 (30.7)
4 35 (25.2) 39 (19.0)
5 13 (9.4) 26 (12.7)
Note - CL = Clinical lipodystrophy, MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass index.
Table 2 BMI by gender and clinical lipodystrophy
Men Women
BMI
[kg/m2, (n (%)]
Without CL With CL Without CL With CL
< 18.5 1 (1.2) 9 (5.8) 0 (0.0) 8 (15.4)
≥18.5 and < 25 38 (44.7) 88 (57.1) 16 (30.2) 25 (48.1)
≥25 and < 30 31 (36.5) 47 (30.5) 20 (37.7) 15 (28.8)
≥30 15 (17.6) 10 (6.5) 17 (32.1) 4 (7.7)
p value 0.009 < 0.001
Note - CL = Clinical lipodystrophy; BMI = body mass index.
Table 3 Metabolic syndrome prevalence according to ATP
III and IDF criteria in the total of patients and by gender
and presence of clinical lipodystrophy
MS Criteria Total of patients Without CL With CL P
ATP III [n, (%)]
Total 180 (52.2%) 71 (51.1%) 109 (52.9%) 0.738
Men 130 (54.4%) 46 (54.1%) 84 (54.5%) 0.949
Women 50 (47.2%) 25 (46.3%) 25 (48.1%) 0.854
IDF [n, (%)]
Total 149 (43.2%) 64 (46.0%) 85 (41.3%) 0.379
Men 88 (36.8%) 36 (42.4%) 52 (33.8%) 0.188
Women 61 (57.5%) 28 (51.9%) 33 (63.5%) 0.227
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third
Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF
= International Diabetes Federation; BMI = body mass index.
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(121 patients); p = 0.442 for IDF]]. No significant differ-
ences according to gender and presence of CL were
observed regarding the prevalence of the MS (Table 3).
However, men and women with lipodystrophy had a sig-
nificantly different prevalence of the MS when stratified
by BMI classes, regardless the criteria used to define the
MS (Table 4). Men and women with CL presented a sig-
nificantly higher prevalence of the MS in the normal and
underweight class (Table 4). A significantly higher preva-
lence of hypertriglyceridemia, low HDL-C levels and
lower prevalence of abdominal obesity were observed in
patients with CL. No differences were found in the num-
ber of the MS features according to ATPIII and IDF cri-
teria in patients with and without CL (Table 1).
Regarding the aggregate of the MS criteria using the
ATP definition, the most frequent aggregate number was
2, except for men without CL. On the other hand, using
the IDF definition, the most frequent aggregate number
was 3, except for women without CL (table 5 and 6). No
significant increase of MS prevalence with age was
observed in patients with or without CL (data not shown).
Concerning the frequency of the individual ATPIII cri-
teria for MS, we found a significantly lower prevalence
of central obesity in men with CL and no other signifi-
cant differences were observed. No significant differ-
ences were found in the frequency of the five IDF
criteria for the MS in men (table 5).
In women with CL, using either ATPIII or IDF cri-
teria, we found a statistically higher frequency of hyper-
triglyceridemia and lower HDL-C levels. According to
ATPIII criteria, women with CL had a lower frequency
of central obesity (Table 6).
No significant differences were found between the
cumulative number MS features according to the pre-
sence of CL in both genders (Table 5 and 6).
In men, high blood pressure, high WC and the MS
were more frequent in those with isolated central fat
accumulation and mixed forms of lipodystrophy using
either ATPIII or IDF criteria. High fasting glucose levels
were significantly more frequent in patients with isolated
central fat accumulation and mixed forms of lipodystro-
phy using ATPIII criteria and without any differences
(p = 0.058) in the 4 groups of fat distribution using the
IDF criteria (table 7).
In women, no significant differences were found in high
blood pressure and high fasting glucose levels in the four
groups of fat distribution (either ATPIII or IDF criteria).
Hypertriglyceridemia, low C-HDL levels, high waist cir-
cumference and presence of the MS were more frequent
in patients with isolated central fat accumulation and
mixed forms of lipodystrophy using either ATPIII or IDF
criteria (table 8).
Men and women with CL, after adjustment for age and
cART, had significantly lower odds of having central obe-
sity, as defined by the ATPIII criteria [OR = 0.403 (95%
CI: 0.187-0.865) and OR = 0.306 (95%CI: 0.118-0.796),
respectively].
In women, CL was significantly associated with higher
odds of having MS as defined by IDF [OR = 5.290 (95%
CI: 1.502-18.635)], hypertriglyceridemia [OR = 5.917
(95%CI: 1.50-23.349)] and low HDL cholesterol [OR =
3.990 (95%CI:1.252-12.716)], independently of age,
cART and BMI (tables 9 and 10).
No significant differences were found in the five
classes of the Framingham risk score between patients
with or without CL (data not shown).
Patients with CL had a significantly higher median risk
of coronary heart disease at 10 years, measured by the
Framingham risk score, than patients without CL, [med-
ian (25th and 75th percentile) = 7.00 (4.00-14.00) and
6.00 (4.00-11.00); p = 0.049]. Independent of the pre-
sence of CL, those with MS had a higher median of the
Framingham risk score. In patients without CL, those
with MS had a higher Framingham risk score median
than those without MS, [median (25th and 75th percen-
tile) = 7.00 (4.00-12.50) and 6.00 (3.00-9.00); p = 0.007].
Also, in patients with CL, those with MS, had a higher
Framingham risk score than those without MS, [median
(25th and 75th percentile) = 9.00 (6.00-18.00) and 6.00
(4.00-9.00); p < 0.001].
In patients with CL, we found significant differences
in the Framingham risk score classes between patients
with or without MS. Patients with CL and with MS had
higher frequencies of moderate and high risk categories
than those without MS (table 11).
Table 4 MS prevalence by BMI, gender and clinical
lipodystrophy according to ATPIII criteria and IDF
Men Women
Without CL With CL Without CL With CL
ATPIII criteria
Classes of BMI
[kg/m2; (n (%)]
< 25 14 (30.4%) 41 (48.8%) 3 (12.5%) 11 (44.0%)
≥25 < 30 19 (41.3%) 33 (39.3%) 9 (37.5%) 10 (40.0%)
≥30 13 (28.3%) 10 (11.9%) 12 (50.0%) 4 (16.0%)
p value 0.002 < 0.001 0.012 0.008
IDF criteria
< 25 4 (11.1%) 11 (21.2%) 5 (18.5%) 16 (48.5%)
≥25 < 30 18 (50.0%) 32 (61.5%) 10 (37.0%) 13 (39.4%)
≥30 14 (38.9%) 9 (17.3%) 12 (44.4%) 4 (12.1%)
p value < 0.001 < 0.001 0.084 0.012
Note - CL = Clinical lipodystrophy; MS = Metabolic syndrome; ATPIII = Third
Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF
= International Diabetes Federation; BMI = body mass in
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Discussion
To our knowledge, this is the first study conducted in
HIV-infected patients focusing specifically on the role of
subcutaneous adipose tissue atrophy defined by presence
of CL on the prevalence of the MS. Another particular-
ity is that all patients were on cART. Other studies ana-
lysed the presence of the MS in naïve or on cART HIV-
infected patients, with sub-analyses concerning the pre-
sence of CL in patients with the MS [12,14,17].
cART can induce a large spectrum of metabolic distur-
bances. On the other hand, lipodystrophy per se, including
genetic lipodystrophy syndromes, is associated with lipid
and metabolic disturbances, and hasmany similarities with
the MS [2,31-35]. The effect of cART on the molecular
processes of metabolic disturbances has been extensively
studied [36] and its contribution to an increased risk of
premature and accelerated atherosclerosis in HIV infec-
tion is well recognized [37,38]. Our aim was to determine
the different patterns of metabolic alterations in patients
with or without lipodystrophy.
It is unknown if the MS is more frequent in patients
with lipodystrophy compared to either with patients
without lipodystrophy and not HIV-infected [9,17]. We
found a higher prevalence of MS compared with some
studies [9,10,12-23] but similar to another [11]. We
included all patients referred from the Infectious Diseases
Table 5 Frequency of each criterion of MS according to ATP III and IDF in men with and without clinical lipodystrophy
Men
ATPIII IDF
MS criteria Total Without CL With CL p value Total Without CL With CL p value
WC [n, (%)] 43 (18.0%) 21 (24.7%) 22 (14.3%) 0.045 98 (41.0%) 42 (49.4%) 56 (36.4%) 0.050
TG [n, (%)] 197 (82.4%) 65 (76.5%) 132 (85.7%) 0.072 197 (82.4%) 65 (76.5%) 132 (85.7%) 0.072
HDL [n, (%)] 181 (75.7%) 62 (72.9%) 119 (77.3%) 0.455 181 (75.7%) 62 (72.9%) 119 (77.3%) 0.455
BP [n, (%)] 111 (46.6%) 41 (48.2%) 70 (45.8%) 0.713 111 (46.6%) 41 (48.2%) 70 (45.8%) 0.713
GLU [n, (%)] 107 (44.8%) 35 (41.2%) 72 (46.8%) 0.407 103 (43.1%) 35 (41.2%) 68 (44.2%) 0.656
Number of MS criteria
0 8 (3.3) 3 (3.5) 5 (3.3) 8 (3.4) 3 (3.5) 5 (3.3)
1 29 (12.1) 15 (17.6) 14 (9.2) 24 (10.1) 11 (12.9) 13 (8.5)
2 72 (30.1) 21 (24.7) 51 (33.3) 60 (25.29 19 (22.4) 41 (26.8)
3 67 (28.5) 23 (27.1) 44 (28.8) 70 (29.4) 22 (25.9) 48 (31.4)
4 48 (20.1) 17 (20.0) 31 (20.3) 48 (20.2) 20 (23.5) 28 (18.3)
5 14 (5.9) 6 (7.1) 8 (5.2) 0.411 28 (11.8) 10 (11.8) 18 (11.8) 0.718
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; WC = waist circumference; TG = triglycerides; HDL = HDL
cholesterol; BP = blood pressure; GLU = glucose.
Table 6 Frequency of each criterion of MS according to ATP III and IDF in women with and without clinical
lipodystrophy
Women
ATPIII IDF
MS criteria Total Without CL With CL p Total Without CL With CL p
WC [n, (%)] 61 (57.5%) 37 (68.5%) 24 (46.2%) 0.020 83 (78.3%) 45 (83.3%) 38 (73.1%) 0.200
TG [n, (%)] 78 (73.6%) 33 (61.1%) 45 (86.5%) 0.003 78 (73.6%) 33 (61.1%) 45 (86.5%) 0.003
HDL [n, (%)] 72 (67.9%) 31 (57.4%) 41 (78.8%) 0.018 72 (67.9%) 31(57.4%) 41 (78.8%) 0.018
BP [n, (%)] 37 (34.9%) 20 (37.0%) 17 (32.7%) 0.639 37 (34.9%) 20 (37.0%) 17 (32.7%) 0.639
GLU [n, (%)] 28 (26.4%) 16 (29.6%) 12 (23.1%) 0.444 28 (26.4%) 16 (29.6%) 12 (23.1%) 0.444
Number of MS criteria
0 7 (6.6) 3 (5.6) 4 (7.7) 0.680 6 (5.7) 2 (3.7) 4 (7.7) 0.214
1 15 (14.2) 10 (18.5) 5 (9.6) 12 (11.3) 8 (14.8) 4 (7.7)
2 34 (32.1) 16 (29.6) 18 (34.6) 26 (24.5) 16 (29.6) 10 (19.2)
3 16 (15.1) 8 (14.8) 8 (15.4) 25 (23.6) 10 (18.5) 15 (28.8)
4 25 (23.6) 14 (25.9) 11 (21.2) 26 (24.5) 15 (27.8) 11 (21.2)
5 9 (8.5) 3 (5.6) 6 (11.5) 11 (10.4) 3 (5.6) 8 (15.4)
Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; WC = waist circumference; TG = triglycerides; HDL = HDL
cholesterol; BP = blood pressure; GLU = glucose.
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Department to our Endocrinology Out-patient Clinic for
metabolic abnormalities, but we cannot exclude the
selection bias by the infectious disease specialist. We
found a high prevalence of lipodystrophy but there was
no selection bias for the presence of isolated lipoatrohy
or abdominal prominence. Since our main goal was to
evaluate whether the presence of lipodystrophy influ-
ences MA, only patients on cART were included. The
high MS prevalence may reflect the fact that all the
patients were on cART. Another important fact is the
low prevalence of intravenous drug users in our study
(24.6% in patients without CL and 30.6% in patients with
CL) compared with Jericó study (41.3%), which con-
curred on the low prevalence of abdominal obesity.
Studies of prevalence of MS in HIV-infected indivi-
duals compared with control populations revealed differ-
ent prevalences of MS) [9-23] and it also seems to be
higher than the 22 to 24% prevalence rate reported for
the general US population [39]. Other data suggest that
the increased prevalence of MS among HIV-infected
persons may be reflective of the burgeoning epidemic of
obesity than a predominant effect of cART [40]. Cigar-
ette smoking analysis could be important because of its
frequent association with lower BMI and higher glucose
Table 7 Metabolic syndrome and its individual components according the four different groups of fat distribution in
men
Four different groups of fat distribution
[n (%)] No
lipodystrophy
Isolated central
fat accumulation
Isolated
lipoatrophy
Mixed forms
of lipodystrophy
P
ATP III
High blood pressure 17 (39.5) 24 (57.1) 36 (37.1) 33 (60.0) 0.017
Hypertriglyceridemia 32 (74.4) 33 (78.6) 79 (81.4) 52 (92.9) 0.086
Low HDL cholesterol 29 (67.4) 33 (78.6) 74 (76.3) 44 (78.6) 0.563
High waist circumference 0 (0.0) 21 (50.0) 0 (0.0) 22 (39.3) < 0.001
High fasting glucose 13 (30.2) 22 (52.4) 40 (41.2) 32 (57.1) 0.035
Metabolic syndrome 16 (37.2) 30 (71.4) 43 (44.3) 40 (71.4) < 0.001
IDF
High blood pressure 17 (39.5) 24 (57.1) 36 (37.1) 33 (60.0) 0.017
Hypertriglyceridemia 32 (74.4) 33 (78.6) 79 (81.4) 52 (92.9) 0.086
Low HDL cholesterol 29 (67.4) 33 (78.6) 74 (76.3) 44 (78.6) 0.563
High waist circumference 0 (0.0) 42 (100.0) 0 (0.0) 56 (100.0) < 0.001
High fasting glucose 13 (30.2) 22 (52.4) 38 (39.2) 30 (53.6) 0.058
Metabolic syndrome 0 (0.0) 36 (85.7) 0 (0.0) 52 (92.9) < 0.001
Table 8 Metabolic syndrome and its individual components according the four different groups of fat distribution in
women
Four different groups of fat distribution
[n (%)] No
lipodystrophy
Isolated central
fat accumulation
Isolated
lipoatrophy
Mixed forms
of lipodystrophy
P
ATP III
High blood pressure 1 (11.1) 19 (42.2) 2 (14.3) 15 (39.5) 0.110
Hypertriglyceridemia 4 (44.4) 29 (64.4) 8 (57.1) 37 (97.4) < 0.001
Low HDL cholesterol 5 (55.6) 26 (57.8) 8 (57.1) 33 (86.8) 0.021
High waist circumference 0 (0.0) 37 (82.2) 0 (0.0) 24 (63.2) < 0.001
High fasting glucose 2 (22.2) 14 (31.1) 1 (7.1) 11 (28.9) 0.335
Metabolic syndrome 0 (0.0) 25 (55.6) 1 (7.1) 24 (63.2) < 0.001
IDF
High blood pressure 1 (11.1) 19 (42.2) 2 (14.3) 15 (39.5) 0.110
Hypertriglyceridemia 4 (44.4) 29 (64.4) 8 (57.1) 37 (97.4) < 0.001
Low HDL cholesterol 5 (55.6) 26 (57.8) 8 (57.1) 33 (86.8) 0.012
High waist circumference 0 (0.0) 45 (100.0) 0 (0.0) 38 (100.0) < 0.001
High fasting glucose 2 (22.2) 14 (31.1) 1 (7.1) 11 (28.9) 0.348
Metabolic syndrome 0 (0.0) 28 (62.2) 0 (0.0) 33 (86.8) < 0.001
Freitas et al. BMC Infectious Diseases 2011, 11:246
http://www.biomedcentral.com/1471-2334/11/246
Page 7 of 11
levels, however, no significant difference was found in
smoking history (never, current or former) between
patients with or without CL. Also, no significant differ-
ence was found in fasting plasma glucose levels accord-
ing the smoking history.
In our sample, the prevalence of MS was lower using
the IDF definition compared to the ATPIII criteria
either in the total of the patients or in men with or
without CL. On the other hand, in women it was higher
when the IDF definition was used. This probably mir-
rors the fact that central obesity is a compulsory criter-
ion for the IDF definition, and, women had a higher
mean of WC. Since HIV patients despite lower WC had
increased visceral fat, Capeau J proposed that a different
WC cut-off is needed for HIV patients [34]. In fact, in
our data, patients with CL after adjustment for age and
cART had significantly lower odds of having central
obesity.
No differences in the prevalence of ATPIII or IDF
defined MS between patients with and without CL were
observed, like it was previously described by Estrada
[14]. In women, CL was significantly associated with
MS, hypertriglyceridemia and low HDL cholesterol inde-
pendently of age, cART and BMI. Analyzing the data
differently, Samaras showed that the prevalence of CL
was 57.2% in the total of patients, and 73% and 79% in
Table 9 Association between lipodystrophy and the metabolic syndrome and its individual components in men
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
MS ATP III 1.017 (0.598-1.731) 0.621 (0.324-1.191) 0.931 (0.460-1.884)
High waist circumference 0.508 (0.260-0.991) 0.403 (0.187-0.865) –
Hypertriglyceridemia 1.846 (0.940-3.624) 1.677 (0.782-3.600) 2.019 (0.899-4.531)
Low HDL cholesterol 1.261 (0.686-2.319) 1.116 (0.562-2.216) 1.304 (0.639-2.661)
High fasting glucose 1.254 (0.734-2.143) 1.004 (0.540-1.868) 1.256 (0.654-2.409)
High blood pressure 0.905 (0.532-1.540) 0.458 (0.223-0.939) 0.567 (0.270-1.191)
MS IDF 0.694 (0.402-1.196) 0.519 (0.274-0.985) 1.058 (0.473-2.365)
High waist circumference 0.585 (0.342-1.001) 0.491 (0.260-0.929) –
Hypertriglyceridemia 1.846 (0.940-3.624) 1.677 (0.782-3.600) 2.019 (0.899-4.531)
Low HDL cholesterol 1.261 (0.686-2.319) 1.116 (0.562-2.216) 1.304 (0.639-2.661)
High fasting glucose 1.130 (0.661-1.931) 0.940 (0.506-1.743) 1.143 (0.599-2.180)
High blood pressure 0.905 (0.532-1.540) 0.458 (0.223-0.939) 0.567 (0.270-1.191)
Model 1 - OR crude.
Model 2 - OR adjusted for gender, age and cART.
Model 3 - OR adjusted for gender, age, duration of cART and BMI.
Table 10 Association between lipodystrophy and the metabolic syndrome and its individual components in women
Modelo 1
OR (95% CI)
Modelo 2
OR (95% CI)
Modelo3
OR (95% CI)
MS ATP III 1.074 (0.501-2.303) 0.763 (0.298-1.952) 2.730 (0.810-9.194)
High waist circumference 0.394 (0.178-0.869) 0.306 (0.118-0.796) –
Hypertriglyceridemia 4.091 (1.557-10.750) 3.091 (1.063-8.989) 5.917 (1.50-23.349)
Low HDL cholesterol 2.765 (1.174-6.513) 2.308 (0.885-6.020) 3.990 (1.252-12.716)
High fasting glucose 0.713 (0.298-1.701) 0.560 (0.204-1.534) 0.758 (0.240-2.390)
High blood pressure 0.826 (0.371-1.839) 0.511 (0.177-1.474) 0.917 (0.273-3.078)
MS IDF 1.613 (0.742-3.507) 1.461 (0.572-3.736) 5.290 (1.502-18.635)
High waist circumference 0.543 (0.212-1.393) 0.385 (0.127-1.164) –
Hypertriglyceridemia 4.091 (1.557-10.750) 3.091 (1.063-8.989) 5.917 (1.500-23.349)
Low HDL cholesterol 2.765 (1.174-6.513) 2.308 (0.885-6.020) 3.990 (1.252-12.716)
High fasting glucose 0.713 (0.298-1.701) 0.560 (0.204-1.534) 0.758 (0.240-2.390)
High blood pressure 0.826 (0.371-1.839) 0.511 (0.177-1.474) 0.917 (0.273-3.078)
Model 1 - OR crude.
Model 2 - OR adjusted for gender, age and cART.
Model 3 - OR adjusted for gender, age, duration of cART and BMI.
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those with MS defined by respectively IDF and ATPIII
criteria [17]. In our patients, we did not find any signifi-
cant differences in the prevalence of lipodystrophy in
patients with and without MS, according to both cri-
teria. In the Jericó study, as in Samaras, lipodystrophy
was more common among MS participants (50.4 vs
33.8; p = 0.0001) [12], and Squillace, also found that CL
was strongly associated with MS [22].
In the Jericó and Mangili studies, the prevalence of MS
in HIV-infected patients significantly increased with age
[12]. In our sample, we did not observe any differences in
the distribution of MS prevalence according to age. This
may reflect the homogeneity of age strata in our sample,
when compared to other studies (only 12% of our sample
were 60 years or older).
Regarding gender differences, as in our study, Mangili
reported that significantly more women than men had
MS [10].
Concerning the number of MS components, in our
study and according to IDF definition, we had 25% of
patients with two features of MS which is lower when
compared to other studies [12,17]. In the Samara study,
49% of patients had at least two features of MS, namely
elevated lipid levels [17]. In the Jericó study, the MS pre-
valence was 17%, with 69.3% of patients showing one or
more features of MS, 35.8% two or more, 4.5% three or
more and 0.1% five features [12].
Concerning the prevalence of the individual features of
MS, we found that the two least prevalent features were
high fasting glucose level (similar to Bonfatti and Sobieszc-
zyk) [18,21] and high WC, the latter being the least preva-
lent in the patients with CL. Lipid abnormalities, namely
high triglyceride and low HDL-C levels, were present in all
HIV-infected patients [9,10,12,13,16,17] and also in CL
patients, the most prevalent components of MS. Obesity is
an important risk factor for MS in the general population
and in HIV-infected individuals [40]. We found a higher
prevalence of overweight and obesity among the patients
without CL. Although not proving causation, because of
the cross-sectional nature of the study design, we can
hypothesize that the high frequency of overweight and
obesity in patients without CL may contribute to the
observed absence of difference in the MS prevalence
between patients with or without CL. To clarify the rela-
tion between obesity and MS as well as the alterations in
the fat distribution, data was analysed according to the
presence or absence of either lipoatrophy or abdominal
prominence. In men, high blood pressure and MS were
more frequent in those with isolated central fat accumula-
tion and mixed forms of lipodystrophy (ATPIII and IDF
criteria) and high fasting glucose levels were significantly
more frequent in same two groups using ATPIII criteria.
In women, hypertriglyceridemia, low C-HDL levels, high
WC and presence of MS were more frequent in those
with isolated central fat accumulation and mixed forms of
lipodystrophy using either ATPIII or IDF criteria. The
observation that patients with CL had significantly higher
risk of coronary heart disease at 10 years, measured by the
Framingham risk score, than patients without CL and that
those with CL and with MS had higher frequencies of
moderate and high risk categories than those without MS
emphasizes the importance of the clinical diagnosis of this
condition. The higher risk of CHD at 10 years of HIV lipo-
dystrophic patients was previously reported by Ena [41]. In
the De Socio study, a correlation between the Framingham
risk score and MS was observed, and patients with lipody-
strophy had a higher Framingham risk score than patients
without lipodystrophy, suggesting that the presence of
lipodystrophy has metabolic implications equivalent to
those of MS [42].
Our study had some limitations. We did not exclude
patients with diabetes or hypertension diagnosed prior to
HIV infection. We also cannot discard the influence of
the pre-HIV body composition, the cumulative exposure
time of each drug and the nadir value of CD4 factors that
could contribute to the risk lipoatrophy or abdominal
prominence that were not evaluated. It is difficult to
compare results on the prevalence of MS because of the
heterogeneity in populations regarding past and actual
cART regimens and treatment adherence. Regarding the
CD4 count we only presented the values at the time of
the cross sectional evaluation, because we did not have
access to the nadir value. Finally, there exists the possibi-
lity of selection bias. Some subjects in this study were
referred from to Endocrinology Clinics specifically for
lipodystrophy or metabolic disorders related to cART,
Table 11 Framingham risk score according clinical lipodystrophy and metabolic syndrome
Without clinical lipodystrophy With clinical lipodystrophy
Framingham risk score Without MS With MS Total Without MS With MS Total
Low risk (< 5%) [n (%)] 27 (45.8) 20 (29.4) 47 (37.0) 36 (41.9) 23 (21.5) 59 (30.6)
Average (5%-9%) [n (%)] 21 (35.6) 22 (32.4) 43 (33.9) 31 (36.0) 31 (29.0) 62 (32.1)
Moderate risk (10-19%) [n (%)] 7 (11.9) 13 (19.1) 20 (15.7) 15 (17.4) 31 (29.0) 46 (23.8)
High risk (20-39%) [n (%)] 3 (5.1) 12 (17.6) 15 (11.8) 2 (2.3) 20 (18.7) 22 (11.4)
Very high risk (> 40%) [n (%)] 1 (1.7) 1 (1.5) 2 (1.6) 2 (2.3) 2 (1.9) 4 (2.1)
p 0.078 < 0.001
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and so we might have selected for a study population
enriched for metabolic complications.
Conclusions
In women, CL was significantly associated with the
metabolic syndrome, hypertriglyceridemia and low HDL
cholesterol independent of age, cART and BMI.
Our data showed that among HIV patients on cART,
the prevalence of MS may be remarkably high, especially
when taking into account the mean age of our sample.
The observation that patients with CL had a significantly
higher risk of coronary heart disease at 10 years, measured
by the Framingham risk score, than patients without CL
and those with CL and with MS had higher frequencies of
moderate and high risk categories than those with CL but
without MS, emphasizes the importance of the clinical
diagnosis of this condition.
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